Reporter

October 5, 2021

AstraZeneca seeks emergency approval for COVID-19 antibodies isolated at VUMC

Biopharmaceutical company AstraZeneca has requested emergency use authorization (EUA) from the U.S. Food and Drug Administration for a long-acting antibody combination originally developed at Vanderbilt University Medical Center to protect against COVID-19.

silhouette of three men with guns
October 5, 2021

Breaking bad with Huntington’s disease

Illegal activities are a significant clinical problem in individuals with Huntington’s disease, highlighting the need for improved screening measures and protocols to guide patient management.

October 4, 2021

Neurologic complications of the flu

Neurologic complications are common in children hospitalized with influenza, especially those with chronic neurologic conditions, and are associated with worse outcomes.

October 1, 2021

VUMC research contributed to first COVID-19 pill now under review

Vanderbilt research helped allow pharmaceutical giant Merck & Co. to authorization for the first oral antiviral pill to treat COVID-19.

October 1, 2021

VUMC awarded $31.7 million to harmonize Alzheimer’s research data

Vanderbilt University Medical Center has received a $31.7 million federal grant to harmonize research data gathered on human subjects in scores of disparate studies of Alzheimer’s disease and related dementias.

September 30, 2021

Policy formalizes role and use of medical chaperones during patient encounters

Vanderbilt University Medical Center is implementing a new policy which standardizes and expands the role of a medical chaperone, an individual who serves as a witness for both a patient and their clinician during a sensitive medical examination or procedure.